ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Sells $418,425.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $54.26 on Friday. The company has a fifty day simple moving average of $57.95 and a 200-day simple moving average of $60.13. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -98.65 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a 52-week low of $52.00 and a 52-week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of a number of recent analyst reports. Raymond James increased their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its holdings in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after buying an additional 565,910 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $13,043,000. Millennium Management LLC grew its holdings in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares during the period. Mizuho Markets Americas LLC acquired a new stake in ANI Pharmaceuticals during the third quarter worth about $11,670,000. Finally, Barclays PLC raised its stake in ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after purchasing an additional 135,003 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.